India Stock Market News Updates Today: IndusInd Bank, followed by Dr Reddy's, PowerGrid, Tech Mahindra, M&M, Sun Pharma and Axis Bank were among the top gainers. On the other hand, Maruti, Kotak Bank, SBI and UltraTech Cement were among the losers

Traders said equity markets rose higher today following news of a potential COVID-19 vaccine as AstraZeneca resumed its phase-3 trial. Although, gains were capped as traders also awaited the outcome from the US central bank's two-day policy meeting, scheduled on September 15-16

India Stock Market Highlights Today: Titan, followed by Sun Pharma, HDFC, ICICI Bank, Bajaj Finance, NTPC, HDFC Bank and M&M were among the major gainers on Sensex pack today. On the other hand, Tech Mahindra, HCL Tech, Kotak Bank, ITC and Bharti Airtel were among the laggards

India Stock Market Highlights Today: ICICI Bank, followed by IndusInd Bank, HDFC, ITC, Asian Paints and Titan were among the top losers today. On the other hand, NTPC, PowerGrid, Sun Pharma and Infosys were among the gainers.

Share market updates and analysis for August 11: Factory output data, developments on coronavirus pandemic front and stock specific movements to set tone for stock markets

Share market updates and analysis for July 30: Earnings announcements by Reliance Industries, coronavirus vaccine hopes and US Fed Reserve meeting outcome to set tone for stock markets

India Stock Market Highlights Today: HDFC, followed by Axis Bank, Asian Paints, SBI, ICICI Bank, Kotak Bank, IndusInd Bank and HDFC Bank. On the other hand, Sun Pharma, Reliance Industries, Tech Mahindra and Infosys were among the gainers

Share market updates and analysis for July 22: Corporate earnings announcements, coronavirus vaccine hopes and global cues to set tone for stock markets

Vaccine major Serum Institute of India's CEO Adar Poonawalla said on Monday the company will apply for COVID-19 vaccine trials within a week and will soon begin manufacturing the vaccine, developed by Oxford University, in large volumes

Positive news around the development of a potential coronavirus vaccine and not so weak key economic data from US and China also kept momentum positive  in equity markets worldwide.

Cadila Healthcare stock trades mere points away from its 52-week high of Rs 383.65. Cadila Healthcare stock has risen 4.73% in the last 2 sessions

Coronavirus vaccine update: Moderna has said that it has selected a dose for the final stage of clinical trials. It estimated that the trials would begin in July

Coronavirus vaccine update: Johnson and Johnson has said that it has pushed up clinical trials by two months; Japanese biotech company AnGes Inc expects its coronavirus vaccine to be ready by the first half of 2021 if production and supply goes smoothly

Federation of Indian Micro and Small & Medium Enterprises (FISME) and SME Chamber of India have received complaints from its members about some of the banks making things complicated for struggling small firms

Coronavirus vaccine update: AstraZeneca and Serum Institute of India have signed a licencing agreement to supply 1 billion doses of the Oxford University vaccine to middle and low-income countries, including India

COVID-19 drug: The clinical trial will be conducted across 12 centres in India in 210 patients for 10 days and the results of the clinical trial are expected by October

Stock Market LIVE Updates: Companies set to announce their earnings are State Bank of India, L&T, Jyothi Labs, Exide Industries, Saregama, Alkem Laboratories, Greaves Cotton, Gujarat Gas among others.

Coronavirus vaccine update: Novavax is buying SII's manufacturing plant and planning to produce a billion doses of its coronavirus vaccine by next year

Three clinical trials are undergoing to test Nafamostat in Covid-19 patients; these trials are being led by the University of Tokyo Hospital, Japan; Gyeongsang National University Hospital (South Korea); and a collaborative trial by University Hospital, Italy, University of Zurich, Switzerland and Yokohoma City University, Japan

We have to speed up regulatory processes without compromising on safety, expand manufacturing capacity and build distribution systems. So, instead of $200-300 million, it will cost $2-3 billion, said NITI Aayog member Dr VK Paul